FRAME-001 / CureVac - LARVOL DELTA

A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine. (PubMed, Rev Recent Clin Trials) - "This brief discussion of vaccines and their varieties with examples also discusses vaccine clinical trials in relation to cancer diseases in this DNA and RNA-based cancer vaccine that has had successful clinical trials like the cervical cancer drug VGX-3100, the kidney cancer drug Pembrolizumab, MGN-1601, the prostate cancer drug pTVG-HP with rhGM-CSF, the melanoma cancer drug proteasome siRNA, and the lung cancer drug FRAME-001."

Journal • Review • Bladder Cancer • Cervical Cancer • Genito-urinary Cancer • Infectious Disease • Kidney Cancer • Lung Cancer • Melanoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer. (PubMed, Pharmaceutics) - "The current study describes the development of a clinical grade neoantigen vaccine formulation (FRAME-001) intended as immunotherapy in advanced NSCLC in combination with the immune checkpoint inhibitor pembrolizumab. The presented data show that FRAME-001 is a feasible personalized vaccine formulation for the treatment of stage III-IV NSCLC. The presented data may give guidance in the development of novel personalized therapeutic vaccines since this formulation strategy could be used for any cancer indication."

IO biomarker • Journal • P2 data • Tumor-specific neoantigens • Immune Modulation • Inflammation • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Development of whole Framome personalized cancer vaccines (CIMT 2022) - P2 | "Mouse immunogenicity studies with synthetic long peptides showed that Frame neoantigens are immunogenic and induce both CD8+ and CD4+ T cell responses. We have designed and received authorities approval for the first clinical trial with personalized FRAME-001 peptide cancer vaccine for patients with advanced non-small cell lung cancer with unsatisfactory response to the immune checkpoint inhibition."

IO biomarker • Immune Modulation • Inflammation • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CD8

FRAME-001 Personalized Vaccine in NSCLC (clinicaltrials.gov) - P2; N=15; Not yet recruiting; Sponsor: Frame Pharmaceuticals B.V.

New P2 trial • Immune Modulation • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CD8 • IFNG • IL2 • TNFA